Abstract:Tau and ɑ-synuclein aggregates are the main histopathological hallmarks present in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders. Intraneuronal hyperphosphorylated tau accumulation is significantly connected to the degree of cognitive impairment in AD patients. In particular, the longest 2N4R tau isoform has a propensity to rapidly form oligomers and mature fibrils. On the other hand, misfolding of ɑ-synuclein (α-syn) is the characteristic feature in PD and dementia with Lewy bodies (DLB). There is a strong crosstalk between the two prone-to-aggregation proteins as they coprecipitated in some brains of AD, PD, and DLB patients. Simultaneous targeting of both proteinaceous oligomers and aggregates is still challenging. Here, we rationally designed and synthesized benzothiazole- and indole-based compounds using the structural hybridization strategy between the benzothiazole N744 cyanine dye and the diphenyl pyrazole Anle138b that showed anti-aggregation activity towards 2N4R tau and ɑ-syn, respectively. The anti-aggregation effect of the prepared compounds was monitored using the thioflavin-T (ThT) fluorescence assay, while transmission electron microscopy (TEM) was employed to detect fibrils upon the completion of a time-course study with the ThT assay. Moreover, the photo-induced crosslinking of unmodified protein (PICUP) assay was used to determine the formation of oligomers. Specifically, compounds 46 and 48 demonstrated the highest anti-aggregation activity by decreasing the ThT fluorescence to 4.0 and 14.8%, respectively, against ɑ-synuclein. Although no noticeable effect on 2N4R tau oligomers, 46 showed promising anti-oligomer activity against ɑ-syn. Both compounds induced a significantly high anti-aggregation effect against the two protein fibrils as visualized by TEM. Moreover, compound 48 remarkably inhibited α-syn inclusion and cell confluence using M17D cells. Collectively, compounds 46 and 48 could serve as a basic structure for further optimization to develop clinically active AD and PD disease-modifying agents.

Molecular Design of PTH Derivatives as Tau Protein Inhibitors Using R-Group Search Technology

Design, Synthesis and Biological Evaluation of 2-Styryl-5-hydroxy-4-pyrone Derivatives and Analogues As Multiple Functional Agents with the Potential for the Treatment of Alzheimer's Disease.

Molecular Deformation is a Key Factor in Screening Aggregation Inhibitor for Intrinsically Disordered Protein Tau

Tryptanthrin Analogs Substoichiometrically Inhibit Seeded and Unseeded Tau4RD Aggregation

Artificial intelligence assisted identification of potential tau aggregation inhibitors: ligand- and structure-based virtual screening, in silico ADME, and molecular dynamics study

IDENTIFICATION OF A SMALL MOLECULE INHIBITOR OF TAU AGGREGATION

Computational Insights Into the Inhibition Mechanism of Proanthocyanidin B2 on Tau Hexapeptide (PHF6) Oligomer

Discovery of small molecule benzothiazole and indole derivatives tackling tau 2N4R and a-synuclein fibrils

In silico designed microtubule-stabilizer drugs against tauopathy in Alzheimer's disease

Molecular Hairpin: a Possible Model for Inhibition of Tau Aggregation by Tannic Acid.

Design and synthesis of tacrine-phenothiazine hybrids as multitarget drugs for Alzheimer’s disease

Synthesis and structure-activity relationship (SAR) studies of 1,2,3-triazole, amide, and ester-based benzothiazole derivatives as potential molecular probes for tau protein

A Rational Design to Improve Selective Imaging of Tau Aggregates by Constructing Side Substitution on N,N-dimethylaniline/quinoxaline D-π-A Fluorescent Probe

Design, Synthesis, and Bioactivity of Novel Bifunctional Small Molecules for Alzheimer's disease.

Synthesis and conformational properties of phosphopeptides related to the human tau protein.

Functional Selection of Tau Oligomerization‐Inhibiting Aptamers

[Application of an R-group Search Strategy into Three-Dimensional Quantitative Structure-Activity Relationship of HEA Beta-Secretase Inhibitors and Molecular Virtual Screening].

Selective Degradation of Hyperphosphorylated Tau by Proteolysis-Targeting Chimeras Ameliorates Cognitive Function in Alzheimer’s Disease Model Mice

Tau-Targeted Multifunctional Nanoinhibitor for Alzheimer's Disease.

Exploring Tau Fibril-Disaggregating and Antioxidating Molecules Binding to Membrane-Bound Amyloid Oligomers Using Machine Learning-Enhanced Docking and Molecular Dynamics

Design, synthesis, and biological evaluation of tetrahydropyrimidine analogue as GSK-3β/Aβ aggregation inhibitor and anti-Alzheimer's agent